Should I Supplement Vitamin D in a Patient With Sepsis?

IF 0.8 Q4 EMERGENCY MEDICINE Journal of acute medicine Pub Date : 2024-03-01 DOI:10.6705/j.jacme.202403_14(1).0001
Vedran Kovacic
{"title":"Should I Supplement Vitamin D in a Patient With Sepsis?","authors":"Vedran Kovacic","doi":"10.6705/j.jacme.202403_14(1).0001","DOIUrl":null,"url":null,"abstract":"<p><p>Sepsis is a potentially fatal organ failure produced by the host's immune response to infection. It is critical to identify risk factors associated with a poor prognosis in septic patients in order to develop new therapy options. Vitamin D deficiency (25-hydroxyvitamin cholecalciferol < 20 ng/mL) is common in critical and septic patients. Serum vitamin D concentrations are associated with an increased incidence of mortality in critically ill adult patients. In critically ill patients, vitamin D supplementation (a very high vitamin D <sub>3</sub> or cholecalciferol loading dosage as a single bolus dose ranging from 400,000 to 540,000 IU) is feasible and safe. Some of the trials and their post-hoc analyses evaluating vitamin D supplementation in severely sick individuals, including septic patients, suggested possible benefits in mortality (reduced 28-day mortality in the range of 8.1%-17.5%), and other outcomes (reduction in hospital length in the range from 9 to 18 days, and decrease in duration of mechanical ventilation in the range from 5 to 10 days). Despite the fact that many studies support the provision of vitamin D to septic patients, there are still many studies that contradict this opinion, and there is still debate about the recommendation to use vitamin D in sepsis. A pragmatic clinical approach in severe sepsis could be supplementation of vitamin D if serum levels are diminished (< 30 ng/mL). It appears that a single ultrahigh dose of vitamin D <sub>3</sub> (cholecalciferol) could be administered to the septic patient via an enteral tube, followed by daily or monthly maintenance doses. Parenteral administration might be reserved for a subgroup of septic patients with gastrointestinal, hepatic, or renal dysfunction. Future clinical trials designed exclusively for septic patients are required to assess the potential advantages of vitamin D. Possible impacts of selective activators of vitamin D receptors, such as paricalcitol, should be elucidated in sepsis. This emphasizes the requirement for more study and confirmation of any potential beneficial effects of vitamin D in sepsis.</p>","PeriodicalId":14846,"journal":{"name":"Journal of acute medicine","volume":"14 1","pages":"1-8"},"PeriodicalIF":0.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10933588/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of acute medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6705/j.jacme.202403_14(1).0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Sepsis is a potentially fatal organ failure produced by the host's immune response to infection. It is critical to identify risk factors associated with a poor prognosis in septic patients in order to develop new therapy options. Vitamin D deficiency (25-hydroxyvitamin cholecalciferol < 20 ng/mL) is common in critical and septic patients. Serum vitamin D concentrations are associated with an increased incidence of mortality in critically ill adult patients. In critically ill patients, vitamin D supplementation (a very high vitamin D 3 or cholecalciferol loading dosage as a single bolus dose ranging from 400,000 to 540,000 IU) is feasible and safe. Some of the trials and their post-hoc analyses evaluating vitamin D supplementation in severely sick individuals, including septic patients, suggested possible benefits in mortality (reduced 28-day mortality in the range of 8.1%-17.5%), and other outcomes (reduction in hospital length in the range from 9 to 18 days, and decrease in duration of mechanical ventilation in the range from 5 to 10 days). Despite the fact that many studies support the provision of vitamin D to septic patients, there are still many studies that contradict this opinion, and there is still debate about the recommendation to use vitamin D in sepsis. A pragmatic clinical approach in severe sepsis could be supplementation of vitamin D if serum levels are diminished (< 30 ng/mL). It appears that a single ultrahigh dose of vitamin D 3 (cholecalciferol) could be administered to the septic patient via an enteral tube, followed by daily or monthly maintenance doses. Parenteral administration might be reserved for a subgroup of septic patients with gastrointestinal, hepatic, or renal dysfunction. Future clinical trials designed exclusively for septic patients are required to assess the potential advantages of vitamin D. Possible impacts of selective activators of vitamin D receptors, such as paricalcitol, should be elucidated in sepsis. This emphasizes the requirement for more study and confirmation of any potential beneficial effects of vitamin D in sepsis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
我应该为败血症患者补充维生素 D 吗?
败血症是宿主对感染的免疫反应导致的潜在致命性器官衰竭。确定与败血症患者预后不良相关的风险因素以开发新的治疗方案至关重要。维生素 D 缺乏(25-羟维生素胆钙化醇 < 20 ng/mL)在危重病人和脓毒症患者中很常见。血清维生素 D 浓度与成年重症患者死亡率的增加有关。在危重病人中,补充维生素 D(维生素 D 3 或胆钙化醇的负荷剂量非常高,单次栓剂剂量从 400,000 到 540,000 IU 不等)是可行且安全的。一些对重症患者(包括败血症患者)补充维生素 D 进行评估的试验及其事后分析表明,补充维生素 D 可降低死亡率(28 天死亡率降低了 8.1%-17.5%)和其他结果(住院时间缩短了 9 到 18 天,机械通气时间缩短了 5 到 10 天)。尽管许多研究都支持为脓毒症患者提供维生素 D,但仍有许多研究与这一观点相悖,关于在脓毒症患者中使用维生素 D 的建议仍存在争议。在严重脓毒症中,如果血清中的维生素 D 水平降低(< 30 ng/mL),可以采取一种务实的临床方法来补充维生素 D。脓毒症患者似乎可以通过肠管服用一次超大剂量的维生素 D 3(胆钙化醇),然后每天或每月服用一次。肠外给药可保留给胃肠道、肝脏或肾脏功能障碍的败血症患者。未来需要进行专门针对脓毒症患者的临床试验,以评估维生素 D 的潜在优势。应阐明维生素 D 受体选择性激活剂(如帕立骨化醇)对脓毒症可能产生的影响。这强调了对维生素 D 在脓毒症中的潜在有益作用进行更多研究和确认的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of acute medicine
Journal of acute medicine EMERGENCY MEDICINE-
CiteScore
0.80
自引率
0.00%
发文量
20
期刊最新文献
International Collaboration in Taiwan Emergency Department Publications: A Social Network Analysis. Left Ventricular Perforation Following Transcutaneous Pigtail Catheter Placement Mimicking Anterior Wall Myocardial Infarction: An Unusual Complication. Review of Emamectin Benzoate Poisoning. The Effect of a Separate Flow of Patients With Small Traumatic Injuries on Consult Time and Patient Satisfaction: A Retrospective Cohort Study During COVID-19 in the Emergency Department. Woman With Recurrent Syncope.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1